Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.
Clinical trial NCT01844765 · COMPLETED
Trial details
- NCT number
- NCT01844765
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-08-20
- Primary completion
- 2016-06-01
- Enrollment
- 59
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.